These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 34669432)

  • 21. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
    Huang Q; Ji K; Tian S; Wang F; Huang B; Tong Z; Tan S; Hao J; Wang Q; Tan W; Gao GF; Yan J
    Nat Commun; 2021 Feb; 12(1):776. PubMed ID: 33536425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perspectives and Prospects on mRNA Vaccine Development for COVID-19.
    Jin L; Han Z; Zhao P; Sun K
    Curr Med Chem; 2022; 29(23):3991-3996. PubMed ID: 35170403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations.
    Mirtaleb MS; Falak R; Heshmatnia J; Bakhshandeh B; Taheri RA; Soleimanjahi H; Zolfaghari Emameh R
    Int Immunopharmacol; 2023 Apr; 117():109934. PubMed ID: 36867924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges.
    Malik JA; Ahmed S; Mir A; Shinde M; Bender O; Alshammari F; Ansari M; Anwar S
    J Infect Public Health; 2022 Feb; 15(2):228-240. PubMed ID: 35042059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2.
    Jin Y; Hou C; Li Y; Zheng K; Wang C
    Front Immunol; 2021; 12():821538. PubMed ID: 35126377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. mRNA vaccines for COVID-19: what, why and how.
    Park JW; Lagniton PNP; Liu Y; Xu RH
    Int J Biol Sci; 2021; 17(6):1446-1460. PubMed ID: 33907508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic.
    Chen P; Shi X; He W; Zhong G; Tang Y; Wang H; Zhang P
    Hum Vaccin Immunother; 2022 Dec; 18(1):2040330. PubMed ID: 35321627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2.
    Lee KM; Lin SJ; Wu CJ; Kuo RL
    Biomed J; 2023 Feb; 46(1):70-80. PubMed ID: 36642222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
    Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
    Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19 mRNA vaccines.
    Huang Q; Zeng J; Yan J
    J Genet Genomics; 2021 Feb; 48(2):107-114. PubMed ID: 34006471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms.
    Jafari A; Danesh Pouya F; Niknam Z; Abdollahpour-Alitappeh M; Rezaei-Tavirani M; Rasmi Y
    Mol Biol Rep; 2022 Jun; 49(6):4943-4957. PubMed ID: 35235159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses.
    Gounant V; Ferré VM; Soussi G; Charpentier C; Flament H; Fidouh N; Collin G; Namour C; Assoun S; Bizot A; Brouk Z; Vicaut E; Teixeira L; Descamps D; Zalcman G
    J Thorac Oncol; 2022 Feb; 17(2):239-251. PubMed ID: 34798306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [SARS-CoV-2 vaccines].
    Benfield TL; Helweg-Larsen J
    Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. mRNA vaccines for COVID-19 and diverse diseases.
    Hussain A; Yang H; Zhang M; Liu Q; Alotaibi G; Irfan M; He H; Chang J; Liang XJ; Weng Y; Huang Y
    J Control Release; 2022 May; 345():314-333. PubMed ID: 35331783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The vaccine journey for COVID-19: a comprehensive systematic review of current clinical trials in humans.
    Checcucci E; Piramide F; Pecoraro A; Amparore D; Campi R; Fiori C; Elhage O; Kotecha P; Vyakarnam A; Serni S; Dasgupta P; Porpiglia F
    Panminerva Med; 2022 Mar; 64(1):72-79. PubMed ID: 32456404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2: Unique Challenges of the Virus and Vaccines.
    Mahmoodpoor A; Sanaie S; Samadi P; Yousefi M; Nader ND
    Immunol Invest; 2021 Oct; 50(7):802-809. PubMed ID: 34109900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.
    Olariu TR; Ursoniu S; Marincu I; Lupu MA
    Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946275
    [No Abstract]   [Full Text] [Related]  

  • 38. Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination.
    Bisgin A; Sanlioglu AD; Eksi YE; Griffith TS; Sanlioglu S
    Hum Gene Ther; 2021 Jun; 32(11-12):541-562. PubMed ID: 33858231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).
    Bennet BM; Wolf J; Laureano R; Sellers RS
    Toxicol Pathol; 2020 Oct; 48(7):800-809. PubMed ID: 32926660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.